Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health"
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM. The School’s first fully endowed corporate chair, it will support vital research into reducing 5.3 million child deaths in low and middle-income countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190515006091/en/
Takeda’s donation will enable LSHTM to recruit a world-class researcher and educator to join its innovative academic team as the first holder of the Takeda Chair in Global Child Health. This post will play a critical role in consolidating LSHTM’s child health research across more than 100 countries, accelerating change for one of the biggest global health challenges, and further strengthening LSHTM’s position as a leader in maternal, child and adolescent health.
Christophe Weber, President and CEO of Takeda, stated, “Takeda’s aim is to thrive at the cutting edge of innovation that helps solve unmet medical needs, both through our own R&D and in collaboration with exceptional partners across the globe. We believe that global health research and the training of new global healthcare professionals are essential to the ongoing translation of science into life-changing therapies for patients. This Chair does both. We are excited to partner with LSHTM, renowned for its pioneering research and uniquely placed to realize the full potential impact of the Chair, and in doing so directly benefitting millions of children and their families.”
Through its Corporate Social Responsibility (CSR) activities, Takeda has supported health worker training and capacity building, immunization campaigns, health system strengthening and maternal, child and newborn health in the developing world for over a decade. Additionally, Takeda has a long history of supporting child health beyond CSR. For over 70 years, the company has supplied critical vaccines to the children of Japan, and more recently is working to expand impact on global health beyond Japan through a pipeline with the potential to transform the global picture for several neglected diseases.
More than five million children under the age of five die each year, half of whom die within the neonatal period (birth to one month old), with the next largest number being due to childhood infections such as pneumonia and diarrhea. While the vast majority of these deaths are preventable, key research gaps remain. The Takeda Chair in Global Child Health will enable a ‘rising star’ to bridge research, public policy, and healthcare delivery by developing thought leadership in child survival and health through innovative research, including vaccines, neonatal care, under-nutrition, and infection diagnostics and treatments.
Professor Baron Peter Piot, Director of LSHTM, stated, “We are honored to partner with Takeda to create this Professorial Chair, the first in our School’s history to have been fully endowed through corporate support. This donation is incredibly valuable, providing ongoing funding and support for a Professorial Chair in Global Child Health – a pivotal part of our continuing mission to improve health worldwide. We are deeply thankful to Takeda for their generosity as we work together to transform the health of future generations.”
Professor Joy Lawn, Director of LSHTM’s MARCH Centre (Maternal Adolescent, Reproductive & Child Health Centre), said, “The Takeda Chair will advance the evidence base for child survival and child health around the world, enable innovations and drive an important emphasis on the science and realities of healthcare implementation. This Chair will be instrumental in linking evidence to action, especially in sub-Saharan Africa and South Asia, where the majority of child deaths occur. We are grateful for Takeda’s generous support which will advance child health worldwide, and aligns with the mission of the London School of Hygiene & Tropical Medicine and our school’s MARCH Centre.”
International recruitment for the Takeda Chair in Global Child Health will begin in May. Due to the perpetual nature of this endowment, this role will be awarded to generations of academics, enabling the best and brightest academic minds to have the freedom to explore innovative ways to improve global health.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
About the London School of Hygiene & Tropical Medicine
The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with 4,500 students and more than 3,000 staff working in over 100 countries. LSHTM is one of the highest-rated research institutions in the UK, and among the world's leading schools in public and global health. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice. For more information, visit www.lshtm.ac.uk and https://march.lshtm.ac.uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515006091/en/
Contact information
Media Inquiries:
The Press Office at LSHTM
press@lshtm.ac.uk
+44(0)207
927 2802
Takeda Pharmaceutical Company
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81
3 3278 2095
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 12:13:00 EEST | Press release
SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release
The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom